Eton Pharmaceuticals Secures FDA Nod for DESMODA, Aims for $30-50M Peak Sales
Event summary
- Eton Pharmaceuticals received FDA approval for DESMODA (desmopressin acetate) Oral Solution on February 25, 2026.
- DESMODA is the first and only FDA-approved oral liquid formulation of desmopressin, designed for precise dosing in central diabetes insipidus.
- Commercial launch expected March 9, 2026, with peak sales projected at $30-50 million annually.
- Patent protection extends through 2044, positioning DESMODA as a long-term growth driver.
The big picture
Eton Pharmaceuticals’ FDA approval for DESMODA aligns with its strategy of developing differentiated therapies for rare endocrine diseases. The product’s precise dosing solution addresses a critical gap in managing central diabetes insipidus, potentially positioning Eton as a key player in the rare disease space. With peak sales estimates ranging from $30-50 million and patent protection extending through 2044, DESMODA could become a foundational therapy in this niche market.
What we're watching
- Market Penetration
- Whether Eton can effectively capture the estimated 13,000 U.S. patients with central diabetes insipidus.
- Competitive Dynamics
- How DESMODA’s precise dosing will differentiate it from existing desmopressin formulations.
- Execution Risk
- The pace at which Eton can scale commercialization and achieve projected peak sales.
Our editorial coverage:
Related topics